ArticleJournal of market access & health policy2017

Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years.

Borislav Borissov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.